CYP3A and CYP2B6 Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study

Long-term antiretroviral treatment (cART) increases the risk of glucose metabolism disorders (GMDs). Genetic variation in drug-metabolizing enzymes and transporters may influence susceptibility to cART-associated GMDs. We conducted a case-control study to investigate the association of pharmacogenetic variations with cART-induced GMDs. A total of 240 HIV patients on long-term efavirenz-based cART (75 GMD cases and 165 controls without GMDs) were genotyped for CYP3A4*1B, CYP3A5 (*3,*6), CYP2B6*6, UGT2B7*2, ABCB1 (c.3435C>T, c.4036A>G), and SLCO1B1 (*1b, *5). GMD cases were defined as the presence of impaired fasting glucose, insulin resistance, or diabetes mellitus (DM). Case-control genotype/haplotype association and logistic regression analysis were performed by adjusting for age, sex, and BMI. The major CYP3A haplotype were CYP3A5*3 (53.8%), CYP3A4*1B (17.3%), combinations of CYP3A4*1B, and CYP3A5*6 (10.9%), and CYP3A wild type (7%). CYP3A5*6 allele (p = 0.005) and CYP3A5*6 genotype (p = 0.01) were significantly associated with GMD cases. Multivariate analysis indicated CYP3A haplotype as a significant predictor of GMD (p = 0.02) and IFG (p = 0.004). CYP2B6*6 significantly predicted DM (p = 0.03). CYP3A haplotype and CYP2B6*6 genotype are independent significant predictors of GMD and DM, respectively, among HIV patients on long-term EFV-based cART.

[1]  Amy E. Chadwick,et al.  Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  W. Amogne,et al.  Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy , 2022, PloS one.

[3]  B. T. Tadesse,et al.  Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study , 2021, Journal of personalized medicine.

[4]  E. Aklillu,et al.  Effect of Pharmacogenetics Variations on Praziquantel Plasma Concentrations and Schistosomiasis Treatment Outcomes Among Infected School-Aged Children in Tanzania , 2021, Frontiers in Pharmacology.

[5]  C. Farquhar,et al.  Increased risk of prediabetes among virally suppressed adults with HIV in Central Kenya detected using glycated haemoglobin and fasting blood glucose , 2021, Endocrinology, diabetes & metabolism.

[6]  H. Fox,et al.  Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells , 2021, Frontiers in Immunology.

[7]  Alimuddin Zumla,et al.  Early or deferred initiation of efavirenz during rifampicin‐based TB therapy has no significant effect on CYP3A induction in TB‐HIV infected patients , 2020, British journal of pharmacology.

[8]  A. Kefale,et al.  Health related quality of life of people receiving highly active antiretroviral therapy in Southwest Ethiopia , 2020, PloS one.

[9]  C. Sudfeld,et al.  Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations , 2020, Frontiers in Pharmacology.

[10]  C. Vigouroux,et al.  Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment , 2019, Expert opinion on drug safety.

[11]  B. T. Tadesse,et al.  HIV and cART-Associated Dyslipidemia Among HIV-Infected Children , 2019, Journal of clinical medicine.

[12]  B. T. Tadesse,et al.  Hepatic and renal toxicity and associated factors among HIV‐infected children on antiretroviral therapy: a prospective cohort study , 2018, HIV medicine.

[13]  L. Bertilsson,et al.  Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin , 2018, European Journal of Clinical Pharmacology.

[14]  Tiancheng Xie,et al.  CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients , 2018, European Journal of Clinical Pharmacology.

[15]  S. Massawe,et al.  Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women , 2017, Malaria Journal.

[16]  E. Aklillu,et al.  Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation. , 2017, Omics : a journal of integrative biology.

[17]  E. Aklillu,et al.  HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians , 2017, Front. Pharmacol..

[18]  D. Haas,et al.  Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations , 2016, Medicine.

[19]  D. Fitzgerald,et al.  Glucose Metabolism Disorders, HIV and Antiretroviral Therapy among Tanzanian Adults , 2015, PloS one.

[20]  R. Muniyappa,et al.  Assessing Insulin Sensitivity and Resistance in Humans , 2015 .

[21]  I. Schuppe-Koistinen,et al.  Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients , 2014, PloS one.

[22]  U. Nehls,et al.  8-Hydroxy-efavirenz, the Primary Metabolite of the Antiretroviral Drug Efavirenz, Stimulates the Glycolytic Flux in Cultured Rat Astrocytes , 2013, Neurochemical Research.

[23]  A. Hurlé,et al.  Impact of pharmacogenetics on CNS side effects related to efavirenz. , 2013, Pharmacogenomics.

[24]  L. Bertilsson,et al.  Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations , 2013, PloS one.

[25]  L. Gustafsson,et al.  Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study , 2013, BMC Infectious Diseases.

[26]  C. Dandara,et al.  ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients , 2012, Front. Gene..

[27]  L. Lindquist,et al.  Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania , 2012, PloS one.

[28]  L. Lindquist,et al.  Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients , 2011, PloS one.

[29]  W. Haefeli,et al.  High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study , 2011, The Pharmacogenomics Journal.

[30]  U. Diczfalusy,et al.  Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians , 2011, The Pharmacogenomics Journal.

[31]  N. Apostolova,et al.  Enhanced oxidative stress and increased mitochondrial mass during Efavirenz‐induced apoptosis in human hepatic cells , 2010, British journal of pharmacology.

[32]  L. Milani,et al.  A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. , 2009, British journal of clinical pharmacology.

[33]  Michael M Gottesman,et al.  A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. , 2009, Biochimica et biophysica acta.

[34]  R. Di Lenarda,et al.  Role of MDR1 gene polymorphisms in gingival overgrowth induced by cyclosporine in transplant patients. , 2008, Journal of periodontal research.

[35]  A. Yasunaga,et al.  Association of a polymorphism of ABCB1 with obesity in Japanese individuals. , 2008, Genomics.

[36]  H. Yoshida,et al.  Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus. , 2007, International journal of molecular medicine.

[37]  M. Ingelman-Sundberg,et al.  Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. , 2005, Biochemical and biophysical research communications.

[38]  T. Rebbeck,et al.  Increased transcriptional activity of the CYP3A4*1B promoter variant , 2003, Environmental and molecular mutagenesis.